CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

The reactivation of viruses from latency after allogeneic stem cell transplantation (SCT)
continues to represent a major clinical challenge requiring sophisticated monitoring …

Background Chimeric antigen receptor T (CAR‐T) cell therapy has emerged as a potent
treatment for relapsed or refractory multiple myeloma, demonstrating significant clinical …

Although the use of allogeneic hematopoietic cell transplantation (HCT) for chronic
lymphocytic leukemia (CLL) has declined with the development of novel targeted agents, it …

Polyvalent immunoglobulin is commonly used for desensitization and treatment of antibody‐
mediated rejection in kidney transplantation but its impact on other outcomes is not known …

Cytomegalovirus (CMV), like other herpesviruses, has the unique ability to establish latent
infection with subsequent reactivation during periods of stress and immunosuppression …

The efficacy of immunoglobulin replacement therapy (IgRT) has been demonstrated for
primary immune deficiency diseases and hematological malignancies such as chronic …

Secondary immunodeficiency (SID) can occur as a result of multiple factors, including
hematological malignancies, hematopoietic stem cell transplantation (HSCT) …

Immunoglobulin replacement to prevent infections in people with haematological malignancies
and haematopoietic stem cell transplantation - PMC Back to Top Skip to main content NIH NLM …

CMV represents one of the most severe life-threatening complications of allogeneic stem
cell transplantation (allo-SCT). Pre-emptive treatment is highly effective, but toxicity and …